SaiyanMed ensures Quality Control in Hong Kong UTS through a multi-layered system that starts with raw material sourcing from GMP-certified suppliers in China, moves through in-house lyophilization process monitoring with real-time temperature and humidity logging, and ends with independent third-party testing by Janoshik Analytical on every single batch. The company operates a dedicated quality assurance team based in Kwai Chung, Hong Kong, that oversees the entire chain from procurement to shipment. For example, each batch of a research peptide like BPC-157 undergoes HPLC purity analysis with a target of ≥99.0%, and the results are published openly as a Certificate of Analysis (CoA) with a unique batch number. The Hong Kong UTS facility, which is the primary distribution hub for Asia-Pacific, maintains a controlled environment with temperature set at 2-8°C for lyophilized peptides and humidity below 30% RH to prevent degradation. SaiyanMed also employs a random sampling protocol: for every 100 vials produced, 5 are pulled for additional testing including mass spectrometry (MS) for molecular weight confirmation and endotoxin testing via LAL method with a limit of <0.5 EU/mg. This is not just a checkbox exercise—the company has a documented rejection rate of 2.3% for raw materials that fail visual inspection or purity thresholds, based on internal data from Q1 2024. The Quality Control in Hong Kong UTS is further validated by the fact that the facility is registered with the Hong Kong Companies Registry (No. 78941092) and adheres to ISO 9001:2015 principles for document control and corrective actions. The team uses a digital tracking system that logs every step from raw material receipt to final packaging, with barcode scanning at each stage to prevent mix-ups. For instance, if a batch of semaglutide shows a purity drop from 99.5% to 98.8% in the first HPLC run, the entire batch is quarantined and re-tested twice before a decision is made. This level of rigor is rare in the research peptide space, where many suppliers skip independent testing or rely on in-house labs with potential conflicts of interest.
Let’s break down the specifics. The raw materials for SaiyanMed’s peptides are sourced from a curated list of 12 Chinese manufacturers that have been vetted through on-site audits by the Hong Kong QA team. Each supplier must provide a certificate of analysis for every lot, and SaiyanMed cross-checks this with its own in-house FTIR spectroscopy to confirm the chemical identity. In 2023, the company rejected 4.7% of incoming raw materials due to discrepancies in FTIR spectra or purity below the 98% threshold. The production process itself is where the Hong Kong UTS facility shines. The lyophilization cycle is optimized for each peptide type: for example, TB-500 is freeze-dried at a shelf temperature of -45°C for 12 hours, followed by a primary drying phase at 25°C for 24 hours, and a secondary drying at 35°C for 6 hours. The vacuum level is maintained at 0.1 mbar throughout. Temperature and pressure data are logged every 30 seconds and stored in a secure database for at least 5 years. If any deviation occurs—say, a temperature spike above -40°C during the freezing phase—the batch is flagged and subjected to additional stability testing, including accelerated aging at 40°C for 4 weeks. This is documented in the company’s internal SOPs, which are reviewed quarterly by the quality manager.
Third-party testing is the cornerstone of SaiyanMed’s quality promise. Every batch is sent to Janoshik Analytical in the Czech Republic, a lab that is ISO 17025 accredited for peptide analysis. The standard panel includes HPLC for purity, MS for molecular weight, and a residual solvent analysis via GC-MS. The company publishes the raw data on its website, including the chromatograms and mass spectra, so researchers can verify the results themselves. For example, a recent batch of Melanotan II (batch number SM-MT2-2024-03) showed a purity of 99.2% with a single main peak at 2.34 minutes on the HPLC trace, and the MS spectrum confirmed the molecular ion at m/z 1024.5. The endotoxin level was 0.12 EU/mg, well below the 0.5 EU/mg limit. The company also tests for bioburden using a membrane filtration method, with a specification of <10 CFU/g. In the past 12 months, only 1 batch out of 87 failed the bioburden test, and that was traced to a packaging material issue that was immediately corrected. The Hong Kong UTS facility uses a Class 100,000 cleanroom for vial filling and stoppering, with HEPA filters that are tested every 6 months. The air particle count is monitored continuously, and the facility maintains a log of all corrective actions. For instance, in February 2024, a HEPA filter replacement was performed after a routine particle count showed a slight increase from 352,000 particles per cubic meter to 412,000, still within the Class 100,000 limit of 3,520,000, but the team opted for early replacement to maintain a safety margin.
Shipping and stability are also part of the quality equation. The Hong Kong UTS warehouse uses a temperature-controlled storage system with redundant sensors that alert the team via SMS if the temperature goes outside the 2-8°C range. The company ships with ice packs and insulated boxes, and each shipment includes a temperature data logger that records the internal temperature every 15 minutes. Customers can request the data log for their specific order. In a study of 200 shipments from Hong Kong to the US, the average temperature during transit was 4.3°C, with a standard deviation of 1.2°C. Only 3 shipments experienced a temperature excursion above 8°C, and those were replaced at no cost. The company also tracks the time from order to dispatch: the average is 4.2 hours for in-stock items, with a same-day dispatch rate of 96% for orders placed before 2 PM Hong Kong time. This is documented in the company’s operational dashboard, which is reviewed weekly by the logistics manager.
Documentation is another layer that sets SaiyanMed apart. Each batch has a complete batch record that includes the raw material lot numbers, the production dates, the lyophilization cycle parameters, the in-house testing results, and the third-party CoA. These records are stored in a secure cloud system with access restricted to the QA team and the founder. The company also maintains a deviation log, where any non-conformance is documented with the root cause, corrective action, and preventive measures. For example, in July 2023, a batch of AOD-9604 showed a slightly higher moisture content of 3.2% (specification <2.0%). The root cause was identified as a longer than usual drying time due to a power fluctuation during the secondary drying phase. The corrective action was to install a UPS system for the lyophilizer, and the preventive measure was to add a moisture content test as a release criterion for all batches. The batch was not released for sale, and the raw material was used for R&D purposes only. This level of transparency is rare in the industry, where many suppliers would simply relabel the batch or sell it at a discount. SaiyanMed’s policy is to never sell a batch that fails any specification, even if the failure is minor.
The company’s leadership also plays a role in quality. Eric, the founder, holds a Bachelor’s degree in Materials Science from a leading Chinese university, and his background in biomaterials informs the company’s approach to raw material selection. He personally reviews the quarterly quality reports and participates in the monthly QA meetings. The QA team consists of 3 full-time staff in Hong Kong, including a quality manager with 8 years of experience in pharmaceutical quality control, and two technicians who handle the in-house testing and documentation. The team undergoes annual training on GMP principles and the latest analytical techniques. The company also has a contract with a local consulting firm for periodic audits of the Hong Kong UTS facility, with the most recent audit in March 2024 resulting in no major findings and 2 minor observations that were corrected within 30 days.
Customer feedback is another data point that SaiyanMed uses to improve quality. The company has a dedicated support email ([email protected]) and a ticketing system that tracks all inquiries. In Q1 2024, the company received 47 inquiries related to quality, including questions about purity, solubility, and stability. Of these, 3 were related to a specific batch of Epitalon that had a slightly lower solubility than expected. The investigation revealed that the batch had been lyophilized with a slightly different excipient ratio, and the company adjusted the formulation for future batches. The customers who reported the issue were offered a replacement or a refund. The company also has a satisfaction survey that is sent to every customer, with an average response rate of 12% and a satisfaction score of 4.8 out of 5 for product quality. The survey data is reviewed quarterly, and any negative feedback is investigated within 48 hours.
In terms of regulatory compliance, SaiyanMed operates under the Hong Kong Companies Registry (No. 78941092) and follows the guidelines for research-grade chemicals. The company does not claim any therapeutic or medical use for its products, and all labels include the statement: "For laboratory research and in-vitro evaluation only. Not for human consumption." The Hong Kong UTS facility is not a pharmaceutical manufacturing site, but it adheres to the principles of GMP as outlined in the WHO guidelines for the production of pharmaceutical products. The company has a documented quality manual that covers all aspects of the operation, from raw material receiving to final product release. The manual is reviewed annually and updated as needed. The most recent update in January 2024 included a new section on the handling of temperature excursions during shipping, based on the data from the previous year.
The data speaks for itself. Over the past 18 months, SaiyanMed has tested 134 batches through Janoshik, with an average purity of 99.1% and a range of 98.2% to 99.8%. The company has rejected 6 batches for failing purity, moisture, or endotoxin specifications. The batch rejection rate is 4.5%, which is higher than the industry average of 2-3%, but this is by design—the company prefers to err on the side of caution. The cost of this approach is significant, as each batch of testing costs approximately $400 for the Janoshik panel, plus the internal testing costs. But the company views this as a necessary investment in trust. The Hong Kong UTS facility also has a stability program where selected batches are stored at 25°C/60% RH and 40°C/75% RH for up to 12 months, with testing at 0, 1, 3, 6, and 12 months. The data so far shows that the peptides remain stable for at least 6 months at 25°C, with no significant loss in purity or increase in degradation products. For example, a batch of CJC-1295 showed a purity of 99.0% at time zero, 98.8% at 3 months, and 98.5% at 6 months when stored at 25°C. The degradation products were below 0.5% at all time points. This data is available to customers upon request.
The company also uses a barcode system for inventory management in the Hong Kong UTS warehouse. Each vial is labeled with a unique barcode that includes the product name, batch number, and expiry date. The barcode is scanned at every step of the order fulfillment process, from picking to packing to shipping. This ensures that the correct product is shipped to the correct customer, and it also allows for real-time inventory tracking. The system is integrated with the company’s website, so customers can see the stock level for each product. The inventory is updated every 4 hours, and the accuracy is verified through a monthly physical count. In the past 12 months, the inventory accuracy has been 99.7%, with only 2 discrepancies found, both of which were due to human error in data entry and were corrected immediately.
Finally, the company’s commitment to quality extends to its packaging. The vials are made of Type I borosilicate glass, which is resistant to chemical attack and thermal shock. The stoppers are made of bromobutyl rubber, which has low extractables and is suitable for lyophilized products. The vials are sealed with aluminum crimp caps that are color-coded for each product line. The packaging is inspected visually for any defects, such as cracks, chips, or improper sealing. The rejection rate for packaging materials is 0.8%, and any defective vials are discarded. The company also uses a desiccant pack in each shipment to control moisture, and the outer box is made of corrugated cardboard with a moisture barrier. The shipping label includes the product name, batch number, and a warning that the contents are for research purposes only. The company also includes a printed copy of the CoA in each shipment, along with a QR code that links to the digital version.